Clinical Cure of Bacterial Conjunctivitis with Azithromycin 1%: Vehicle-Controlled, Double-Masked Clinical Trial

American Journal of Ophthalmology

Volumn 145, Issue 6, 2008, Pages 959-965

  Abelson, Mark B ^a,b   Heller, Warren ^c   Shapiro, Aron M ^a   Si, Erwin ^d   Hsu, Peng ^d   Bowman, Lyle M ^d  

^a Ophthalmic Research Associates   (United States)

^b SCHEPENS EYE RESEARCH INSTITUTE   (United States)

^c Arizona Center for Clinical Trials   (United States)

^d InSite Vision   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN;

ADOLESCENT; ADULT; AGED; ARTICLE; BACTERIUM CULTURE; CATARACT; CHEMOSIS; CHILD; CLINICAL TRIAL; CONJUNCTIVA DISEASE; CONJUNCTIVA INJECTION; CONJUNCTIVITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORNEA EROSION; CORNEA STAINING; CORNEA VASCULARIZATION; CORNEAL INFILTRATION; DOUBLE BLIND PROCEDURE; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EYE CHAMBER FLARE; EYE DISCHARGE; EYELID SWELLING; FEMALE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPHTHALMOSCOPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SLIT LAMP; STATISTICAL SIGNIFICANCE; UNSPECIFIED SIDE EFFECT;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; CHILD; CHILD, PRESCHOOL; CONJUNCTIVITIS, BACTERIAL; DOUBLE-BLIND METHOD; FEMALE; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; GRAM-POSITIVE BACTERIA; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; INFANT; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; OPHTHALMIC SOLUTIONS; PROSPECTIVE STUDIES; VEHICLES;

EID: 43949126169     PISSN: 00029394     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajo.2008.01.019     Document Type: Article

References (17)

1. Gigliotti F., Williams W.T., Hayden F.G., et al. Etiology of acute conjunctivitis in children. J Pediatr 98 (1981) 531-536
2. Seal D.V., Barrett S.P., and McGill J.I. Aetiology and treatment of acute bacterial infection of the external eye. Br J Ophthalmol 66 (1982) 357-360
3. Hwang D.G., Schanzlin, Rotberg M.H., Foulks G., Raizman M.B., and Levofloxacin Bacterial Conjunctivitis Place-controlled Study Group. A phase III, placebo controlled clinical trial of 0.5% levofloxacin ophthalmic solution for the treatment of bacterial conjunctivitis. Br J Ophthalmol 87 (2003) 1004-1009
4. Centers for Disease Control and Prevention. Pneumococcal conjunctivitis at an elementary school-Maine, September 20-December 6, 2002. MMWR Morb Mortal Wkly Rep 52 (2003) 64-66
5. American Academy of Ophthalmology. Conjunctivitis, Preferred Practice Pattern (2003), American Academy of Ophthalmology, San Francisco, California. www.aao.org/ppp
6. Jain R., and Danziqer L.H. The macrolide antibiotics: a pharmacokinetic and pharmacodynamic overview. Curr Pharm Des 10 (2004) 3045-3053
7. Protzko E., Bowman L., Abelson M., and Shapiro A. Phase 3 safety comparisons for 1.0% azithromycin in polymeric mucoadhesive eye drops versus 0.3% tobramycin eye drops for bacterial conjunctivitis. Invest Ophthalmol Vis Sci 48 (2007) 3425-3429
8. Kardas P., Devine S., Golembesky A., and Roberts C. A systematic review and meta-analysis of misuse of antibiotic therapies in the community. Int J Antimicrob Agents 26 (2005) 106-113
9. Kass M.A., Hodapp E., Gordon M., et al. Part I. Patient administration of eye drops: interview. Ann Ophthalmol 14 (1982) 775-779
10. Cagle G., Davis S., Rosenthal A., and Smith J. Topical tobramycin and gentamicin sulfate in the treatment of ocular infections: multicenter study. Curr Eye Res 1 (1981-1982) 523-534
11. Kowalski R.P., Yates K.A., Romanowski E.G., et al. An ophthalmologist's guide to understanding antibiotic susceptibility and minimum inhibitory concentration data. Ophthalmology 112 (2005) 1987
12. Abelson M., Protzko E., Shapiro A., Garces-Soldana A., and Bowman L. A randomized trial assessing the clinical efficacy and microbial eradication of 1% azithromycin ophthalmic solution vs tobramycin in adult and pediatric subjects with bacterial conjunctivitis. Clin Ophthalmol 1 (2007) 177-182
13. Romanowski E., Mah F., Yates K., Kowalski R., and Gordon J. The successful treatment of gatifloxacin-resistant Staphylococcus aureus keratitis with Zymar (gatifloxacin 0.3%) in NZW rabbit model. Am J Ophthalmol 139 (2005) 867-877
14. Donnenfeld E., Perry H.D., Chruscicki D.A., Bitterman A., Cohn S., and Solomon R. A comparison of the fourth-generation fluoroquinolones gatifloxacin 0.3% and moxifloxacin 0.5% in terms of ocular tolerability. Curr Med Res Opin 20 (2004) 1753-1758
15. Dutot M., Pouzaud F., Larosche I., Brignole-Baudouin F., Warnet J.M., and Rat P. Fluoroquinolone eye drop induced cytotoxicity: role of preservative in P2X7 cell death receptor activation and apoptosis. Invest Ophthalmol Vis Sci 47 (2006) 2812-2819
16. Berdy G.J., Abelson M.B., Smith L.M., and George M.A. Preservative-free artificial tear preparations. Assessment of corneal epithelial toxic effects. Arch Ophthalmol 110 (1992) 528-532
17. Hand W.L., and Hand D.L. Characteristics and mechanisms of azithromycin accumulation and efflux in human polymorphonuclear leukocytes. Int J Antimicrob Agents 18 (2001) 419-425